Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York. more
Time Frame | OVID | Sector | S&P500 |
---|---|---|---|
1-Week Return | -7.02% | -3.39% | 0.2% |
1-Month Return | 1.92% | -1.92% | 2.72% |
3-Month Return | -5.36% | -10.54% | 7.31% |
6-Month Return | 34.25% | -4.47% | 10.44% |
1-Year Return | -68.55% | 4.06% | 27.53% |
3-Year Return | -67.38% | 0.94% | 30.88% |
5-Year Return | -76.18% | 36.67% | 89.21% |
10-Year Return | -91.35% | 102.87% | 199.95% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 12.62M | 208.38M | 1.50M | 391.69K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":6.05,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":0.72,"profit":true},{"date":"2023-12-31","value":0.19,"profit":true}] |
Cost of Revenue | 255.00K | - | - | 1.38M | 1.60M | [{"date":"2019-12-31","value":15.97,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":86.54,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (255.00K) | 12.62M | 208.38M | 1.50M | 391.69K | [{"date":"2019-12-31","value":-0.12,"profit":false},{"date":"2020-12-31","value":6.05,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":0.72,"profit":true},{"date":"2023-12-31","value":0.19,"profit":true}] |
Gross Margin | (Infinity%) | 100.00% | 100.00% | 100.00% | 100.00% | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 61.41M | 94.05M | 84.17M | 57.05M | 59.67M | [{"date":"2019-12-31","value":65.3,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":89.5,"profit":true},{"date":"2022-12-31","value":60.66,"profit":true},{"date":"2023-12-31","value":63.45,"profit":true}] |
Operating Income | (61.41M) | (81.43M) | 124.21M | (55.55M) | (59.28M) | [{"date":"2019-12-31","value":-49.44,"profit":false},{"date":"2020-12-31","value":-65.56,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-44.72,"profit":false},{"date":"2023-12-31","value":-47.73,"profit":false}] |
Total Non-Operating Income/Expense | 1.90M | - | - | - | 11.84M | [{"date":"2019-12-31","value":16.01,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (60.46M) | (81.04M) | 124.16M | (54.17M) | (52.34M) | [{"date":"2019-12-31","value":-48.69,"profit":false},{"date":"2020-12-31","value":-65.27,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-43.63,"profit":false},{"date":"2023-12-31","value":-42.15,"profit":false}] |
Income Taxes | (1.20M) | (306.85K) | 1.33M | (2.76M) | 5.00 | [{"date":"2019-12-31","value":-90.55,"profit":false},{"date":"2020-12-31","value":-23.09,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-207.76,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (59.26M) | - | - | - | (52.34M) | [{"date":"2019-12-31","value":-5925801700,"profit":false},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-5233896400,"profit":false}] |
Income From Continuous Operations | (60.46M) | (81.04M) | 122.83M | (54.17M) | (48.52M) | [{"date":"2019-12-31","value":-49.22,"profit":false},{"date":"2020-12-31","value":-65.97,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-44.1,"profit":false},{"date":"2023-12-31","value":-39.5,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (59.26M) | (80.73M) | 122.83M | (51.41M) | (52.34M) | [{"date":"2019-12-31","value":-48.24,"profit":false},{"date":"2020-12-31","value":-65.72,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-41.85,"profit":false},{"date":"2023-12-31","value":-42.61,"profit":false}] |
EPS (Diluted) | (1.58) | (1.40) | 2.03 | (0.77) | (0.75) | [{"date":"2019-12-31","value":-77.83,"profit":false},{"date":"2020-12-31","value":-68.97,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-37.93,"profit":false},{"date":"2023-12-31","value":-36.95,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
OVID | |
---|---|
Cash Ratio | 5.39 |
Current Ratio | 5.66 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
OVID | |
---|---|
ROA (LTM) | -36.04% |
ROE (LTM) | -36.61% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
OVID | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.26 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.74 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
OVID | |
---|---|
Trailing PE | NM |
Forward PE | 1.79 |
P/S (TTM) | 119.16 |
P/B | 0.99 |
Price/FCF | NM |
EV/R | 43.74 |
EV/Ebitda | NM |
PEG | NM |
Ovid Therapeutics Inc (OVID) share price today is $1.064
Yes, Indians can buy shares of Ovid Therapeutics Inc (OVID) on Vested. To buy Ovid Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in OVID stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Ovid Therapeutics Inc (OVID) via the Vested app. You can start investing in Ovid Therapeutics Inc (OVID) with a minimum investment of $1.
You can invest in shares of Ovid Therapeutics Inc (OVID) via Vested in three simple steps:
The 52-week high price of Ovid Therapeutics Inc (OVID) is $4.1. The 52-week low price of Ovid Therapeutics Inc (OVID) is $0.68.
The price-to-earnings (P/E) ratio of Ovid Therapeutics Inc (OVID) is
The price-to-book (P/B) ratio of Ovid Therapeutics Inc (OVID) is 0.99
The dividend yield of Ovid Therapeutics Inc (OVID) is 0.00%
The market capitalization of Ovid Therapeutics Inc (OVID) is $75.27M
The stock symbol (or ticker) of Ovid Therapeutics Inc is OVID